GlassScriptPhysician profile
Colman Ross Kraff
NPI 1912953712
$25,446.36
in general payments reported to CMS, 2019-2025
28 companies · $5,240 in 2025
The $5,240 reported for 2025 was more than what 93% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,698 · 2020: $305 · 2021: $6,359 · 2022: $4,363 · 2023: $1,112 · 2024: $1,369 · 2025: $5,240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,500 · Food and Beverage: $3,195 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,500.00 |
| Food and Beverage | $3,195.43 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $15,968.75 | 2019-2025 | Tecnis Iol, Catalys System, Tecnis Simplicity |
| Rxsight INC | $5,806.18 | 2022-2025 | Rxsight Contact Lens, Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Alcon Vision LLC | $836.24 | 2019-2025 | Wavelight Refractive Suite, Eysuvis, Argos |
| Oyster Point Pharma, INC. | $290.33 | 2022-2025 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $276.43 | 2019-2023 | |
| Glaukos Corporation | $250.41 | 2022-2025 | Kxl System (Not Refurbished), Photrexa Viscous and Photrexa, Ce-Marked Kxla System |
| Carl Zeiss Meditec USA, INC. | $240.12 | 2021 | |
| Bausch & Lomb Americas INC. | $235.44 | 2023-2025 | Miebo, Xiidra |
| Sun Pharmaceutical Industries INC. | $213.42 | 2020-2025 | Cequa, Xelpros |
| Kala Pharmaceuticals, INC. | $163.63 | 2019-2022 | |
| Harrow Eye, LLC | $162.77 | 2024-2025 | Vevye |
| Aerie Pharmaceuticals, INC. | $162.46 | 2019-2021 | |
| Biotissue Holdings INC. | $157.16 | 2021-2025 | |
| Tarsus Pharmaceuticals, INC. | $132.73 | 2024-2025 | Xdemvy |
| Abbvie INC. | $97.09 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $68.54 | 2022-2025 | Oxervate |
| Eyevance Pharmaceuticals LLC | $62.85 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $56.15 | 2019-2021 | |
| Allergan, INC. | $42.93 | 2022 | |
| Shire North American Group INC | $37.60 | 2019 | |
| Rayner Intraocular Lenses Limited | $35.94 | 2024 | Omidria |
| Sight Sciences, INC. | $29.30 | 2022-2023 | Tearcare System |
| Mallinckrodt Hospital Products INC. | $25.84 | 2021 | |
| Ocular Therapeutix, INC. | $22.00 | 2020 | |
| Apellis Pharmaceuticals, INC. | $19.64 | 2025 | Syfovre |
| Lensar, INC. | $19.10 | 2023 | Lensar Laser System |
| Horizon Therapeutics Plc | $18.61 | 2022 | |
| Coopervision INC. | $14.70 | 2025 | Myday Contact Lens |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colman Kraff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.